Quarterly report [Sections 13 or 15(d)]

Segment Information

v3.25.2
Segment Information
 6 Months Ended
Jun. 30, 2025
Segment Information [Abstract]  
SEGMENT INFORMATION

NOTE 11 – SEGMENT INFORMATION

 

The Company operates as a single operating segment, as a clinical stage product discovery company developing products using both natural and engineered phage technologies. The Company’s chief operating decision-maker (“CODM”) is its chief executive officer, who reviews financial information presented on a consolidated basis. The CODM uses consolidated Net loss and Operating loss to monitor budget versus actual results in assessing segment performance and the allocation of resources. Significant segment expenses are presented in the Company’s consolidated statements of operations.

 

Additional disaggregated significant segment expenses on a functional basis, that are not separately presented on the Company’s consolidated statements of operations, regularly reviewed by the Company’s CODM, include salaries and clinical trials expenses and presented below.

 

    Three Months Ended
June 30,		     Six Months Ended
June 30,		  
    2025     2024     2025     2024  
Operating expenses:                        
Salaries and related expenses, other than share-based compensation     1,932       3,521       3,909       5,900  
Clinical trials     3,424       3,034       7,049       4,720  
Stock based compensation     696       77       1,355       254  
Depreciation expenses     292       331       528       560  
Other segment items (*)     1,089       2,762       2,348       5,076  
Total Operating expenses     7,433       9,725       15,189       16,510  

 

(*) Other segment items include all remaining costs necessary to operate the Company’s business, which primarily include external professional services, rent, insurance and other administrative expenses, and are presented net of grants received.

 

The Company’s Property and equipment, as well as the Company’s operating lease right-of-use assets recognized on the consolidated balance sheets were located as follows:

 

    As of
June 30,		     As of
December 31,		  
    2025     2024  
Israel     5,516       6,090  
United States     3,688       4,412  
Total     9,204       10,502